NICE Finerenone HFpEF Approval Advances HFpEF Therapy Options

The recent NICE Finerenone HFpEF Approval positions finerenone as a routinely funded treatment for adults with symptomatic chronic heart failure and left ventricular ejection fraction of 40 percent or higher. Evidence shows the therapy reduces worsening heart-failure events compared with placebo while remaining cost-effective treatment against standard thresholds, expanding options without replacing current care standards.

Funding Decision Details

The evaluation draws on one major placebo-controlled trial plus indirect comparisons and real-world data versus spironolactone. A state-transition model based on Kansas City Cardiomyopathy Questionnaire scores tracks progression, with Weibull curves handling mortality risks. NICE Finerenone HFpEF Approval adopts a weighted basket comparator reflecting actual prescribing patterns.

FINEARTS-HF reported a rate ratio of 0.84 for the composite of worsening events and cardiovascular death. Indirect analyses showed neutral hazard ratios for key endpoints, while real-world estimates required adjustment for bias. The resulting £12,764 per quality-adjusted life-year figure held steady in sensitivity testing.

Reimbursement Approach

This framework demonstrates how bodies can handle uneven legacy-therapy uptake without head-to-head trials. Threshold modelling of required finerenone uptake to avoid net loss offers a template for future decisions. NICE Finerenone HFpEF Approval therefore enables earlier access while encouraging further comparative research, including advancing subcutaneous diuretic therapy for heart failure management and first-in-class aldosterone synthase inhibitor approaches alongside NICE cardiorenal protection updates.